“Stem cell therapy for MS” can mean two very different things, and confusing them is one of the biggest challenges for patients researching their options.
The first is HSCT (hematopoietic stem cell transplant), an intensive, hospital-based procedure supported by randomized-trial evidence for a specific group of people with MS. The second is a mesenchymal stem cell (MSC) IV infusion, an outpatient product marketed directly to MS patients by many private clinics, despite having far less evidence behind it.
Neither is FDA approved as a labeled treatment for MS. This guide explains the difference so you can tell which one a clinic, or a search result, is actually referring to.
What HSCT for MS actually is
HSCT uses your own blood-forming stem cells, collected from your bloodstream, to rebuild your immune system after chemotherapy wipes out the cells driving the MS attack on your nervous system. It is the same broad transplant technology used for blood cancers, repurposed here for a small, carefully selected group of MS patients — typically those with active relapsing-remitting MS that keeps progressing despite standard drug therapy.
This is not a walk-in outpatient procedure. HSCT for MS requires hospital admission, a hematology or neuro-immunology team, and weeks of recovery while your immune system rebuilds, with a real risk of infection during that window.
What the evidence shows for HSCT
The strongest evidence comes from the MIST trial, a randomized study published in JAMA in 2019 that assigned 110 patients with active relapsing-remitting MS to either HSCT or continued FDA-approved disease-modifying therapy. Over a mean follow-up of three years, disease progressed in 6% of the HSCT group versus 60% of the drug-therapy group, and average disability scores improved after HSCT while they worsened on continued drug therapy.
That is a meaningfully stronger result than most regenerative-medicine trials in this space, which is why HSCT gets discussed differently from other “stem cell” offers. It is still not a cure, it does not reverse existing nerve damage, and it carries real transplant-related risks, which is why it is reserved for patients whose MS keeps progressing on standard drugs rather than offered as a first-line option.
What the MSC infusions many clinics sell are
Separately, a number of private clinics — inside and outside the US — market an IV infusion of mesenchymal stem cells directly to MS patients, often advertised simply as “stem cell therapy for MS.” This is a different product from HSCT: no immune-resetting chemotherapy, an outpatient visit, and a much thinner evidence base.
The FDA has warned specifically about this category, naming MS among the conditions one such unapproved product was marketed to treat, and has stated broadly that no regenerative medicine product is approved for any neurological disorder, MS included. A registered clinical trial of umbilical-cord-derived MSC infusion for MS is still collecting data as of 2025 — meaning the question of whether this specific approach helps is still open, not yet answered.
What it costs
HSCT at a US academic transplant center typically costs $70,000 to $120,000, according to published health-economics research on US MS transplant programs. That sounds high until you compare it with the cost of standard MS disease-modifying drugs, which commonly run $80,000 to $100,000 per year and continue indefinitely — making HSCT’s one-time cost potentially cost-saving over several years for the specific patients it fits.
Private-clinic MSC infusions marketed for MS are priced very differently: commonly several thousand dollars up to $20,000 or more per round, paid entirely out of pocket, with many clinics recommending repeat infusions. Because these clinics operate outside FDA oversight, there is no standard price and no refund norm if the infusion does not help.
Is either one covered by insurance?
HSCT coverage is inconsistent. Because it is not FDA-approved as a labeled MS therapy, many insurers classify it as investigational and deny it, while others approve it case by case, particularly when performed within a registered clinical trial. If you are considering HSCT, ask the transplant center directly what portion, if any, your specific insurer has covered for past patients.
MSC infusions from private clinics are essentially never covered. No major insurer recognizes them as a covered MS treatment, so the full cost falls on you regardless of outcome.
How to tell which one you’re being offered
Ask three questions before you go further with any “stem cells for MS” conversation:
- Is this an inpatient transplant program run by a hematologist or neuro-immunologist, or an outpatient IV infusion? HSCT is never a same-day outpatient visit.
- Does the provider require documented, active relapsing disease on your MRI and exam history? A legitimate HSCT program screens hard for candidacy; a clinic that will infuse anyone regardless of MS type or activity level is not running an HSCT program.
- Is the price several thousand dollars for a single infusion, or a large lump sum tied to a hospital admission? The price point alone is a strong signal for which product you are actually looking at.
The bottom line
“Stem cell therapy for MS” hides two different things: HSCT, an intensive transplant with real randomized-trial evidence for a specific group of relapsing MS patients, and private-clinic MSC infusions, an outpatient product with a far thinner evidence base that the FDA has specifically warned about. Neither carries FDA approval as a labeled MS treatment. If you are exploring either path, start with a neurologist who treats MS, not a clinic’s marketing page, and read our clinic red-flag checklist before you pay anyone a deposit.
Frequently asked questions
Is stem cell therapy for MS FDA approved?
No product marketed as stem cell therapy for MS is FDA approved. The FDA has stated that no regenerative medicine product is approved to treat multiple sclerosis, ALS, Alzheimer's, Parkinson's, epilepsy, or stroke, and has issued warning letters against companies marketing unapproved cell products directly for MS.
What's the difference between HSCT and 'stem cell therapy' for MS?
HSCT (hematopoietic stem cell transplant) uses your own blood-forming stem cells to reset an overactive immune system and is studied in real randomized trials at specialized transplant centers. The 'stem cell therapy for MS' sold by many private clinics is usually an IV infusion of mesenchymal stem cells (MSCs), a different product with far less trial evidence, marketed directly to consumers rather than delivered through a research protocol.
Does HSCT work for MS?
For a specific group of patients with active relapsing-remitting MS, a randomized trial found HSCT delayed disease progression more than continued drug therapy. It is not a cure, is not FDA-approved as a labeled MS treatment, and carries real transplant risks, so it is offered only at specialized centers after other treatments have been tried.
How much does stem cell therapy for MS cost?
HSCT for MS costs roughly $70,000 to $120,000 in the US when performed at an academic transplant center, which is comparable to a year or two of standard MS drug therapy. Private-clinic MSC infusions for MS are unregulated and typically run several thousand to over $20,000 per round, are not covered by insurance, and often recommend repeat rounds.
Is HSCT covered by insurance for MS?
Sometimes, though coverage is inconsistent. Because HSCT is not FDA-approved as a labeled MS treatment, many insurers treat it as investigational and deny coverage; others cover it case by case, especially within a clinical trial. Private-clinic MSC infusions are essentially never covered, since they have no established evidence base to support a coverage claim.
Are private clinics selling 'stem cells for MS' the same as academic HSCT programs?
No. A legitimate HSCT program requires a hematology or transplant specialist, a demonstrated relapsing pattern on your MRI and exam history, and inpatient transplant-level care. A clinic offering an outpatient IV infusion marketed for MS without any of that is selling the unapproved MSC product the FDA has warned about, not HSCT.
Medical disclaimer. Medical Frontier is an independent educational resource. This page is for general information only and is not medical advice, diagnosis, or treatment, and does not create a doctor–patient relationship. Most regenerative therapies discussed here are not FDA-approved for the uses described and may be offered under limited exemptions or in clinical trials only. Always consult a licensed physician before making any treatment decision.